Q-omics provides the consensus-scored RPS17P1 profile across patient tissues and cancer cell-line models. RPS17P1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPS17P1 is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, RPS17P1 RNA expression shows 8,303 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight SKCM, BLCA, and COAD as cancer lineages where RPS17P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS17P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS17P1 survival associations across molecular data types. RPS17P1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS17P1 RNA expression–survival associations across cancer types. High RPS17P1 expression shows unfavorable associations in ACC and MESO, but favorable associations in SKCM, KIRC, PAAD and THYM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPS17P1 RNA expression.
This table summarizes RPS17P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS17P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS17P1 shows lower tumor expression in BLCA, BRCA, LUAD, LUSC, STAD and PRAD. The BLCA box plot shows higher RPS17P1 RNA expression in normal versus tumor tissue (log2 FC = −0.514, t-test p < 0.001).
This table shows molecular features associated with RPS17P1 in patient tissues and cancer cell lines. In patient samples, RPS17P1 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
